Clinical trials: Histological Response
Hematologic Disorder
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect…
- Trial name
- NCT01924169
- Testing
- Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
Hepatocellular Carcinoma, HCC
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness…
- Trial name
- NCT01871545
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non-functioning Pituitary Adenomas, Prolactinomas
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
There are no available medical treatment options for patients with non-functioning pituitary adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured by surgery.
- Trial name
- NCT01620138
- Testing
- Pasireotide, cabergoline
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Adenocarcinoma, Rectal Neoplasms
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemoradiotherapy (CRT) followed by extensive surgery regardless of tumor response.
- Trial name
- NCT01171300
- Testing
- 18F- FDG PET scans, DW-MRI scans
- Where
- Belgium
- Volunteers
- 94 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Diffuse Large B-Cell Lymphoma, DLBCL
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
This is a prospective, multicenter, multi-cohort study of ctDNA combined with PET for predicting the efficacy of standard first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT07070648
- Testing
- POLA-R-CHP
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes
The goal of this clinical trial is to learn whether postoperative immunotherapy combined with anlotinib can help prevent or delay cancer recurrence in adults aged 18 to 75 years with locally advanced esophageal squamous cell…
- Trial name
- NCT07830355
- Testing
- Anlotinib, Anti-PD-1 Monoclonal Antibody
- Volunteers
- 75 people
- Sponsor
- Shanghai Chest Hospital
Multiple Myeloma
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as…
- Trial name
- NCT01134484
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Michele Cavo
Medication Reconciliation
Pharmacist Discharge Medication Reconciliation Study
Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list…
- Trial name
- NCT01226589
- Testing
- MRS
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Alberta Health services
Thymoma
Preoperative Treatment of Patients With High Risk Thymoma
This is a phase II study for patients with thymoma or thymic carcinoma thought to be at significant risk for recurrence following surgical removal.
- Trial name
- NCT00387868
- Testing
- cisplatin and etoposide, Surgical Resection, Concurrent Radiotherapy
- Where
- 2 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Valley Health System
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Glioblastoma
Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma
This trial is a translational, open-label, monocentric prospective study of 80 patients aiming to study resistance mechanisms as well as biomarkers of resistance or sensitivity to TTFields.
- Trial name
- EXOFIELDS (NCT06222138)
- Testing
- The samples described below will be collected:
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Leukemia, Myeloid, Chronic-Phase (CML-CP)
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).
- Trial name
- NCT01188278
- Testing
- Imatinib
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb
Adult Glioblastoma, Magnetic Resonance Imaging
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.
- Conditions
- Adult Glioblastoma, Magnetic Resonance Imaging, Bevacizimab
- Trial name
- NCT04143425
- Testing
- 3-Tesla conventional magnetic resonance imaging, Advanced imaging without contrast use, Dynamic susceptibility contrast-weighted imaging
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Ho Sung Kim
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
The goal of this clinical trial is to assess the 1-year DFS rate of toripalimab adjuvant therapy in participants with resected esophageal squamous cell carcinoma (ESCC) who achieved pCR.
- Trial name
- NCT06903871
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Hebei Medical University Fourth Hospital
Meningioma
Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide
Meningiomas are the most common primary tumors of the central nervous system, representing more than a third of tumors.Current conventional treatments for meningioma are surgery and radiotherapy.
- Trial name
- MELUTE (NCT06255249)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Myeloma
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
In this study, the investigators will analyze the long-term outcomes of remission and survival, and identify those with primary resistant disease as more likely to benefit from CTD (thalidomide, cyclophosphamide, dexamethasone)…
- Trial name
- KMM-97 (NCT01114048)
- Testing
- Thalidomide, cyclophosphamide, dexamethasone, bortezomib
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Chonnam National University Hospital
Glioblastoma, Glioma
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients.
- Trial name
- AVA-CELL (NCT01836536)
- Testing
- Bevacizumab standard of care
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Center Eugene Marquis
NeuroEndocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in…
- Trial name
- CALM-NET (NCT02075606)
- Testing
- lanreotide acetate
- Where
- 14 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Ipsen
Epithelial Ovarian Cancer
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
The primary objectives of the study are: 1. To delineate commonly utilized tumor metabolic alterations in ovarian cancer. These metabolic alterations will be explored for potentially targetable pathways to restore chemotherapy…
- Trial name
- NCT07764133
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Tennessee Graduate School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.